NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Cassava Sciences Inc (SAVA) Stock Analysis

Cassava Sciences Inc (SAVA) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

SAVA

$1.29

−$0.02 (−1.15%)

Last trade May 11, 2026

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare SAVA with… →

SAVA Key Statistics

As of May 11, 2026
Trading
Open
$1.28
Previous Close
$1.30
Day's Range
1.28–1.35
52-Week Range
1.15–4.98
Volume
234.77K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−0.84
Valuation
Market Cap
$114.97M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−2.22
Financials (FY)
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
1-Year Return
−27.40%
Dividend and dates
Avg Volume
777.18K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

SAVA Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−35.10%
2025−16.10%
2024 (partial year)+3.06%

As of May 11, 2026.

SAVA Valuation vs Biotechnology Median

Median of 656 stocks
MetricSAVABiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

Cassava Sciences Inc (SAVA) is capitalised at $114.97M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 30 employees.

SAVA last closed at $1.29 on May 11, 2026. That is −$0.02 (−1.15%) against the previous close. The 52-week range on file runs from $1.15 to $4.98. The latest close sits 11.74% above that 52-week low.

Financial Health

The reported profit margin is 0%. Earnings per share on a trailing basis come to −2.22.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

The reported beta is −0.84. Annualized volatility over the trailing 1 year is 90.82%. The trailing one-year price return is −27.40%.

Growth & Income

The record shows no dividend for SAVA.

2026 is still running; the price is −35.10% year to date. The record holds one complete calendar year, 2025, which returned −16.10%.

Peer Comparison

Cassava Sciences Inc (SAVA) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Cassava Sciences Inc SAVA $114.97M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Cassava Sciences Inc has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of May 11, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Cassava Sciences Inc

Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Cassava Sciences, Inc. and changed its name to Filana Therapeutics, Inc. in March 2026. The company was incorporated in 1998 and is based in Austin, Texas.

Visit website →